65,437 trials
Rheumatoid Arthritis
Primary: Safety: Percentage of Participants With Treatment Emergent Adverse /Serious Adverse Events — 90.8; 9.2; 52.3 percentage of participants
Stress Urinary Incontinence
Primary: Number of Participants That Experienced Biopsy Procedure-related Adverse Events — 1 participants
Bipolar Depression
Primary: Change in 17-item Hamilton Depression Rating Scale From Baseline to 8 Weeks (Baseline - 8 Wks) — 7; 9 units on a scale
Solid Tumors
Primary: AUC (0 to Infinity) of Total Selumetinib — 2300; 4300; 1680; 2680 ng*h/mL
Meningitis, Meningococcal, Serogroup B
Primary: Number of Subjects Reporting Unsolicited Adverse Events (AEs). — 0; 0; 0; 0 Subjects
Bipolar Depression
Primary: Change in Hamilton Depression Rating Scale (HDRS-21) Total Score From Baseline at Week 6. — -2.7647; -4; -3.4259; -6.5875 score on scale — p=0.29
Leukemia
Primary: Acute Respiratory Infection (ARI) Days — 8.30; 6.78 days — p=0.295
Dystonia, Focal, Task-specific
Primary: Cortical Silent Period — 9; 1.61 milliseconds
Lymphedema
Primary: LDex Change- — 28.0; 17.8; 22.2 LDex
Chronic Lymphocytic Leukemia
Primary: Progression Free Survival (PFS) Rate — 13.5 Months
Cough · Upper Respiratory Tract Infection
Primary: Change in Night Cough Score on First Night of Treatment (From N0 to N1) — -5.16; -1.77 change in combined night cough score — p=<0.01
Anxiety, Separation · Psychomotor Agitation
Primary: Modified Yale Preoperative Anxiety Scale Scores at Baseline, Arrival in Operating Room, and Inhalation Induction — 28.4; 28.4; 23.4; 23.4 units on a scale
Obesity · Hyperlipidemia · Hypertension
Primary: Change in Physical Activity (Minutes/Week) — 4; 10 min/week
Major Depressive Disorder
Primary: Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score. — -8.20; -7.02…
Prostate Cancer
Primary: Pattern of Response of Serum 25(OH) D3 Levels — 11.34; 24.84; 18.87; 26.91 ng/mL — p=<.0001